Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Short-term Investments: 2012-2025

Historic Short-term Investments for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $156.6 million.

  • Enanta Pharmaceuticals' Short-term Investments fell 25.78% to $156.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.6 million, marking a year-over-year decrease of 25.78%. This contributed to the annual value of $156.6 million for FY2025, which is 25.78% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Short-term Investments stood at $156.6 million for FY2025, which was down 25.78% from $211.0 million recorded in FY2024.
  • Enanta Pharmaceuticals' 5-year Short-term Investments high stood at $284.5 million for FY2023, and its period low was $156.6 million during FY2025.
  • For the 3-year period, Enanta Pharmaceuticals' Short-term Investments averaged around $217.3 million, with its median value being $211.0 million (2024).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Short-term Investments crashed by 37.63% in 2021, and later skyrocketed by 38.63% in 2023.
  • Enanta Pharmaceuticals' Short-term Investments (Yearly) stood at $186.8 million in 2021, then grew by 9.87% to $205.2 million in 2022, then spiked by 38.63% to $284.5 million in 2023, then decreased by 25.86% to $211.0 million in 2024, then fell by 25.78% to $156.6 million in 2025.